Takara Bio

Shiga, JP
CAR-T Lentiviral
8 confirmed programs · 4 sponsors · Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (8) ○ SEC Filings ✓ Press (6)

Quick Facts: Takara Bio

Signal Score
59.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Shiga, JP
Modalities
CAR-T, Lentiviral
Active CGT Programs
8 confirmed from ClinicalTrials.gov across 4 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 8
Sponsors4
ModalitiesCAR-T, Lentiviral
8 active programs across 4 sponsors
Modalities: CAR-T, Lentiviral
5 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07174427 Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel;... PHASE3 Recruiting
NCT05963217 Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen... PHASE1 Recruiting
NCT03250325 Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced... PHASE1/PHASE2 Completed
NCT03155191 Study of TBI-1501 for Relapsed or Refractory Acute... PHASE1/PHASE2 Active Not Recruiting
NCT02418598 AADC Gene Therapy for Parkinson's Disease PHASE1/PHASE2 Terminated
NCT02366546 Investigator Initiated Phase 1 Study of TBI-1301 PHASE1 Unknown
NCT02134262 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR... PHASE1/PHASE2 Unknown
NCT02096614 Investigator Initiated Phase 1 Study of TBI-1201 PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
Regulatory milestones (5 articles)
Sites: Shiga, JP
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press6 articles
Regulatory milestones (5 articles)

Recent News 6 articles

general 2026-03-18
In vivo site-specific engineering to reprogram T cells - Nature
In vivo site-specific engineering to reprogram T cells  Nature
Source →
regulatory 2026-03-13
Stem-Cell Transfection Reagents Market Analysis and Growth Outlook to 2035 - News and Statistics - IndexBox - Market Intelligence Platform
Stem-Cell Transfection Reagents Market Analysis and Growth Outlook to 2035 - News and Statistics  IndexBox
Source →
regulatory 2026-03-13
Immune-Cell Activators Market Fueled by Automated Manufacturing Demands, Forecast to 2035 - News and Statistics - IndexBox - Market Intelligence Platform
Immune-Cell Activators Market Fueled by Automated Manufacturing Demands, Forecast to 2035 - News and Statistics  IndexBox
Source →
regulatory 2026-03-12
Dendritic Cell Media Market to 2035: Driven by First Commercial Approvals for Autologous Cancer Vaccines - IndexBox - Market Intelligence Platform
Dendritic Cell Media Market to 2035: Driven by First Commercial Approvals for Autologous Cancer Vaccines  IndexBox - Market Intelligence Platform
Source →
regulatory 2026-03-11
Cell Culture Media Market Driven by Biologics Manufacturing Boom to Expand Significantly Through 2035 - IndexBox - Market Intelligence Platform
Cell Culture Media Market Driven by Biologics Manufacturing Boom to Expand Significantly Through 2035  IndexBox
Source →
regulatory 2026-03-05
Restriction Enzymes Market Forecast Points Higher Toward 2035, Driven by Synthetic Biology - IndexBox - Market Intelligence Platform
Restriction Enzymes Market Forecast Points Higher Toward 2035, Driven by Synthetic Biology  IndexBox - Market Intelligence Platform
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Lentiviral CDMOs →